Veoza Approved for Menopausal Treatment
Veoza (fezolinetant) has received approval for use on the NHS in England, marking a significant advancement in the treatment of menopausal hot flushes. This new oral medication is aimed at the approximately 500,000 women in England who experience these symptoms and for whom hormone replacement therapy (HRT) is unsuitable.
Hot flushes are a common symptom affecting around 70% of women undergoing menopause, often leading to discomfort and a diminished quality of life. Veoza is designed to alleviate these symptoms by blocking nerve pathways in the brain that trigger hot flushes and night sweats, offering a once-daily oral tablet as a treatment option.
The NHS has set the list price for Veoza at £44.80 for a 28-tablet pack. The National Institute for Health and Care Excellence (NICE) has evaluated fezolinetant and deemed it cost-effective, providing value for taxpayers while addressing a pressing health need.
Helen Knight from NICE emphasized the importance of this treatment, stating, “We know that menopausal hot flushes and night sweats can have a profound impact on quality of life and significantly affect overall wellbeing.” She added that this decision will provide much-needed relief to women who cannot or choose not to take HRT.
Dr. Sue Mann, a prominent figure in women’s health, remarked, “Symptoms of menopause including hot flushes and night sweats can affect every part of a woman’s life, so this is very welcome news especially for women who are unable to or don’t wish to take hormone replacement therapy.” She further noted that Veoza represents a vital treatment option that could help hundreds of thousands of women manage their symptoms more effectively.
For decades, treatment options for menopausal hot flushes have been limited, with many women seeking alternatives to HRT. The introduction of Veoza is expected to change this landscape, providing a new avenue for symptom management.
As the rollout of Veoza begins, healthcare providers and patients alike are optimistic about its potential impact on women’s health. However, details remain unconfirmed regarding the full extent of its availability and distribution across the NHS.
